Sunday, October 4, 2026

Tesla Stock Jumped 3.55% on Wednesday: Will it Correct on The Next Session?

ViaNews Editorial Team

November 26, 2020

Tesla Stock Jumped 3.55% on  Wednesday: Will it Correct on The Next Session?
Tesla shares jumped 3.35% to $574.00 at yesterday, The Nasdaq Stock Market is rose 0.48% to $12,094.40. According to tuesday's article on Bloomberg Quint, "Nikola, Tesla Shares Fall as EV Rally Frenzy Comes to a Halt." According to Tuesday's article on MarketWatch, "Tesla issues recall of 9,000-plus Model X and Model Y vehicles." Tesla's last close was $555.38, 0.05% under its 52-week high of $573.70. Tesla's sales growth is 35.3% for the ongoing quarter and 60% for the next. The company's growth estimates for the ongoing quarter and the next is 112.2% and 265.2%, respectively. Year-on-year quarterly revenue growth grew by 39.2%, now sitting on 28.18B for the twelve trailing months. Tesla's stock is valued at $574.00 at 08:26 EST, above its 52-week high of $573.70. Tesla's worth is way higher than its 50-day moving average of $435.96 and way higher than its 200-day moving average of $332.14. Tesla-heavy etfs ride along as company gets a price upgrade. According to MarketWatch on Mon Nov 23, "Exchovere-traded funds with heavy exposure to Tesla Inc." According to Bloomberg Quint on Tue Nov 24, "Musk Hints Again at Longer-Range Teslas and Hatchback for Europe." According to Bloomberg Quint on Tue Nov 24, "Tesla Nears Half a Trillion Mark After Soaring 525% This Year."
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Citigroup Inc.
Both facts measure EPS for Citigroup with identical observation dates (2025-12-31). FACT A explicitly specifies FY 2025 annual EPS at 6.99 USD/share, while FACT B reports 1.65 USD with an unspecified fiscal period (N/A). The values differ by a factor of ~4.2x, which is too large to explain by rounding, methodology, or data quality variance. While FACT B's 'N/A' fiscal period introduces ambiguity about whether it represents the same annual period, both observations are timestamped identically and purport to measure the same metric on the same date. If both represent FY 2025 annual EPS, this is a direct value conflict. If FACT B represents a different period (e.g., quarterly, TTM, or interim), the ambiguous labeling still constitutes a data quality issue that obscures the reconciliation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com